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Background: It is important to understand the mechanisms by which the cells integrate signals from different
receptors. Several lines of evidence implicate epidermal growth factor (EGF) receptor (EGFR) in the pathophysiology
of hepatocarcinomas. Data also suggest a role of prostaglandins in some of these tumours, through their receptors
of the G protein-coupled receptor (GPCR) family. In this study we have investigated mechanisms of interaction
between signalling from prostaglandin receptors and EGFR in hepatocarcinoma cells.
Methods: The rat hepatocarcinoma cell line MH1C1 and normal rat hepatocytes in primary culture were stimulated
with EGF or prostaglandin E2 (PGE2) and in some experiments also PGF2α. DNA synthesis was determined by
incorporation of radiolabelled thymidine into DNA, phosphorylation of proteins in signalling pathways was assessed
by Western blotting, mRNA expression of prostaglandin receptors was determined using qRT-PCR, accumulation of
inositol phosphates was measured by incorporation of radiolabelled inositol, and cAMP was determined by
radioimmunoassay.
Results: In the MH1C1 hepatocarcinoma cells, stimulation with PGE2 or PGF2α caused phosphorylation of the EGFR,
Akt, and ERK, which could be blocked by the EGFR tyrosine kinase inhibitor gefitinib. This did not occur in primary
hepatocytes. qRT-PCR revealed expression of EP1, EP4, and FP receptor mRNA in MH1C1 cells. PGE2 stimulated
accumulation of inositol phosphates but not cAMP in these cells, suggesting signalling via PLCβ. While
pretreatment with EP1 and EP4 receptor antagonists did not inhibit the effect of PGE2, pretreatment with an FP
receptor antagonist blocked the phosphorylation of EGFR, Akt and ERK. Further studies suggested that the
PGE2-induced signal was mediated via Ca
2+ release and not PKC activation, and that it proceeded through Src and
shedding of membrane-bound EGFR ligand precursors by proteinases of the ADAM family.
Conclusion: The results indicate that in MH1C1 cells, unlike normal hepatocytes, PGE2 activates the MEK/ERK and
PI3K/Akt pathways by transactivation of the EGFR, thus diversifying the GPCR-mediated signal. The data also
suggest that the underlying mechanisms in these cells involve FP receptors, PLCβ, Ca2+, Src, and
proteinase-mediated release of membrane-associated EGFR ligand(s).
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Malignant cells are exposed to a variety of active agents,
including hormones, peptide growth factors, cytokines,
and many other locally acting substances such as prosta-
glandins, which together control or modulate the cellu-
lar functions. It is of interest to understand the
mechanisms by which the cells integrate signals from
different bioactive molecules via their receptors. A not-
able example is the interaction between pathways from
G protein-coupled receptors (GPCRs) and receptor tyro-
sine kinases (RTKs). Studies in many cells have shown
that signals from GPCRs may involve interaction with
the epidermal growth factor receptor (EGFR), an ErbB
family RTK [1-5]. EGFR, which serves important func-
tions in normal cells [6,7], is involved in several malig-
nancies [8,9], and is a target of novel antitumour
therapies [10,11]. In studies including tumour cells from
colon and pancreatic cancer, we have found that differ-
ent mechanisms may be involved in the interaction of
pathways from GPCRs and EGFR [12].
EGFR conveys strong mitogenic stimulation in normal
hepatocytes [13-16], and several lines of evidence sug-
gest a role of EGFR in hepatocarcinogenesis [17-20]. For
example, overexpression of the EGFR agonist transform-
ing growth factor alpha (TGFα) in mice causes hepatic
hyperplasia and tumour formation [21,22], and EGFR is
upregulated in a majority of human hepatocarcinomas
[23]. Inhibition of the EGFR by antibodies or tyrosine
kinase blockers can attenuate the growth of hepatocarci-
noma cells in vitro [24,25], and are currently being
tested in clinical trials in hepatocarcinomas [26].
Prostaglandins, acting through different receptors of
the GPCR family, regulate many cellular functions [27].
In epithelial cells, prostaglandins often enhance prolif-
eration and survival, and several lines of evidence impli-
cate them in oncogenesis [28]. In many tumours,
cyclooxygenases (COX-1 and COX-2), which catalyze
the rate-limiting step in prostaglandin synthesis, are
overexpressed, and the levels of prostaglandins, notably
prostaglandin E2 (PGE2), are elevated [28-31]. In hepato-
cytes, PGE2 and other prostaglandins enhance DNA syn-
thesis [15,32-34], and COX-2 is overexpressed in many
hepatocarcinomas [35,36].
In the study presented here we examined the Morris
hepatocarcinoma cell line MH1C1, which was chosen
due to its responsiveness to both EGF and the prosta-
glandins PGE2 and PGF2α, and investigated the inter-
action between the pathways mediated by prostaglandin
receptors and EGFR. We previously observed that while
there was no evidence of transactivation of EGFR
induced by prostaglandins or other GPCR agonists in
hepatocytes, PGE2 induced phosphorylation of the EGFR
in the MH1C1 cells [37,38]. We have now investigated
further the signalling mechanisms involved in this effect.Methods
Chemicals
Dulbecco’s Modified Eagle's Medium, Dulbecco’s
phosphate-buffered saline, William’s Medium E, glutam-
ine, and Pen-Strep (10.000 U/ml) were from Lonza
(Verviers, Belgium). HEPES was from Gibco (Grand
Island, NY). Dexamethasone, insulin, bovine serum albu-
min, collagen (type I, rat tail), prostaglandin F2α (Tris
salt) and epidermal growth factor (EGF) were obtained
from Sigma-Aldrich (St.Louis, MO). GF109203X ([2-
[1-(3-dimetylaminopropyl)-1H-indol-3-yl]-male-imide])
and GM6001/Galardin (N-[(2R)-2 (hydroxamidocar-
bonylmethyl)-4-methylpentanoyl]-L-tryptophan methyla-
mide) were from Calbiochem (San Diego, CA). Gefitinib
was a gift from AstraZeneca (Cheshire, UK). [6-3 H]-
thymidine (20–30 Ci/mmol) and myo-[2-3 H]inositol
(15.0 Ci/mmol) were from PerkinElmer (Boston, MA).
AL8810 (9α,15R-dihydroxy-11β-fluoro-15-(2,3-dihydro-
1 H-inden-2-yl)-16,17,18,19,20-pentanor-prosta-5Z,13E-
dien-1-oic acid),L161982 (N-[[4'-[[3-butyl-1,5-dihydro-5-
oxo-1-[2-(trifluoromethyl)phenyl]-4 H-1,2,4-triazol-4-yl]
methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-methyl-2-thiophe-
necarboxamide), (+)fluprostenol, and prostaglandin E2
(PGE2) were from Cayman Chemical (Ann Arbor, MI).
SC51322 (8-chloro-2-[3-[(2-furanylmethyl)thio]-1-oxo-
propyl]hydrazide, dibenz[b,f][1,4]oxazepine-10(11 H)-car-
boxylic acid) was obtained from BIOMOL Research
Laboratories (Plymouth Meeting, PA). The Src inhibitor
CGP77675 was a gift from Novartis Pharma AG (Basel,
Switzerland). All other chemicals were of analytical quality.
Antibodies against phosphorylated AktSer473, total Akt,
dually phosphorylated ERKThr202/Tyr204, GAPDH and
phospho-ShcTyr239/240 were obtained from Cell Signaling
Technology (Boston, MA). Antibody against phospho-
EGF receptorTyr1173 was obtained from Invitrogen. Anti-
ERK antibody was from Upstate/Millipore (Billerica,
MA). Secondary antibodies were purchased from Bio-
Rad Laboratories (Hercules, CA) and Licor Biosciences
(Lincoln, NE).
Cells and culturing
The rat hepatocarcinoma cell line MH1C1, derived from
a Morris hepatoma [39], was obtained from ATCC
(Manassas, VA). The cells were seeded onto Costar plas-
tic flasks and cultured in Dulbecco’s Modified Eagle’s
medium. The Medium was supplemented with horse
serum (10%), glutamine (2 mM), and 100 U/ml Pen-
Strep. The cultures were kept in a humidified 5% CO2
incubator at 37°C. Cells were seeded onto culture wells
at a density of 40 000–50 000 cells per cm2. After
24 hours, the medium was changed and the cells were
cultured under serum-free conditions 24 h prior to
stimulation.
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previously described [40]. The hepatocytes were seeded
onto Costar plastic culture wells at a density of 15 000–
20 000 per cm2. The culture medium was a serum-free
1:1 combination of William’s Medium E and Dulbecco’s
Modified Eagle’s Medium. The medium was supplemen-
ted with 100 U/ml Pen-Strep, collagen (3 μg/ml), insulin
(100 nM) and dexamethasone (25 nM).
Immunoblotting
Aliquots containing ~30000 MH1C1 cells or hepatocytes
(total cell lysate prepared in Laemmli or RIPA buffer)
were electrophoresed on 6–12% (w/v) polyacrylamide gels
(acrylamide: N’N’-bis-methylene acrylamide 30:1). This
was followed by protein electrotransfer to nitrocellulose
membranes and immunoblotting with antibodies against
proteins as described in the figures. Usually the same
membrane was stripped and reincubated with different
antibodies, and then one single loading control was used
as the final incubation. Immunoreactive bands were
visualized with enhanced chemiluminescence using Lumi-
GLO (KPL Protein research Products, Gaithersburg, MD)
or by infrared imaging using Odyssey Infrared Imaging
System, supplied by Licor Biosciences (Lincoln, NE).
RNA isolation and cDNA synthesis
RNA from MH1C1 cells was isolated with Qiagen
RNeasy kit according to the manufacturer’s instructions,
and was treated with DNAse. The integrity of RNA was
evaluated by ethidium bromide agarose gel electrophor-
esis, and the quantity and purity was measured spectro-
photometrically (OD 260/280). cDNA was synthesized
from 1.0 μg RNA with Superscript® III reverse transcript-
ase (Invitrogen) according to manufacturer’s protocol.
Reactions without reverse transcriptase were run in par-
allel to control for contamination with chromosomal
DNA. Standard curves with RNA ranging from 0.25 to
2.0 μg of total RNA were made to control for the reverse
transcription and PCR quantification.
Quantitative real-time PCR (qRT-PCR)
The cDNA was analyzed in triplicate by real time quan-
titative PCR on an ABI Prism 7900 HT Sequence de-
tector (Applied Biosystems) with the following cycling
parameters: 50°C for 2 min, 95°C for 10 min and
40 cycles of 15 s at 95°C and 60 s at 60°C, followed by
melting point analysis when using SYBR green. Raw data
were collected and analyzed in the Sequence Detector
Software (SDS ver. 2.2, Applied Biosystems), and cycle of
threshold value (Ct) was calculated from each amplifica-
tion plot. Standard curves (Ct value versus log initial
RNA concentration) were used to calculate the relative
input amount of RNA for each sample based on the Ctvalue [41]. Satisfactory and comparable amplification ef-
ficiency was verified by the slopes of standard curves.
Primers were designed using Primer Express® software
v2.1 (ABI Prism, Applied Biosystems), and were vali-
dated by the production of single products of expected
size on agarose gels, as well as uniformity of melting
temperature, which was routinely performed. Prostaglan-
din receptor cDNA was detected with SYBR Green
methodology and the following primers: EP1: forward
5’ -CCT GCT GGT ATT GGT GGT GTT-3’ and reverse
5’-GGG GTA GGA GGC GAA GAA GTT-3’; EP2: for-
ward 5’-GCT CCC TGC CTT TCA CAA TCT-3’ and
reverse 5’-GGA CTG GTG GTC TAA GGA TGA CA-
3’; EP3: forward 5’-GGT CGC CGC TAT TGA TAA
TGA T-3’ and reverse 5’-CAG GCG AAC GGC GAT
TAG-3‘; EP4: forward 5’-CTC GTG GTG CGA GTG
TTC AT-3’ and reverse 5’-TGT AGA TCC AAG GGT
CCA GGA T-3’; FP: forward 5’-GTC ATT CAG CTC
CTG GCC ATA-3’ and reverse 5’-AGC GTC GTC TCA
CAG GTC ACT-3’. GAPDH cDNA was quantified using
the dual hybridization probe Double Dye oligonucleotide
5’ labelled with the fluorescent dye Yakima yellow and
quenched with Dark Quencher, 5’-CTC ATG ACC ACA
GTC CAT GCC ATC ACT-3’ and the following primers:
forward 5’-CCA AGG TCA TCC ATG ACA ACT T-3’
and reverse 5’-AGG GGC CAT CCA CAG TCT T-3’.
Results were normalized to GADPH.
Accumulation of inositol phosphates and cAMP
[3 H]inositol, 5 μCi/well was added simultaneously with
the serum-free medium. 30 minutes before agonist stimu-
lation for 30 minutes in serum-starved cells, medium was
removed and replaced with Krebs-Ringer-Hepes buffer
pH 7.4, containing 10 mM glucose and 15 mM LiCl.
MH1C1 cells were stimulated with PGE2, fluprostenol or
isoproterenol as indicated, and the reaction was stopped
by removing buffer and adding 1 ml ice-cold 0.4 M per-
chloric acid. Samples were harvested and neutralized with
1.5 M KOH, 60 mM EDTA and 60 mM Hepes, in the
presence of Universal indicator. The neutralized superna-
tants were applied on columns containing 1 ml Dowex
AG 1-X8 resin. The columns were washed with 20 ml
distilled water and 10 ml 5 mM sodium tetraborate/
60 mM ammonium formate, and inositol phosphates
were eluted with 10 ml 1 M ammonium formate/0.1 M
formic acid. cAMP was determined by radioimmunoassay
as previously described [42].
Measurement of DNA synthesis
MH1C1 cells were seeded onto culture wells, and after
24 hours, the medium was changed and the cells were
cultured under serum-free conditions. 24 h after change
to serum-free medium, cells were treated with various
concentrations of gefitinib and harvested at 48 hours,
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synthesis was measured as the amount of radioactivity
incorporated into DNA as previously described [34].
Results
In preliminary experiments we investigated the effect of
PGE2 in the rat hepatocarcinoma cell lines MH1C1,
McA7777, and M4IIE, and the human hepatocarcinoma
cell line HepG2. Although some of these cell lines had
strong responses to EGF (data not shown), the MH1C1
were the only cells showing consistent responses to both
EGF and prostaglandins, and we therefore used these
cells in further experiments.
Transactivation of EGFR induced by PGE2 and PGF2α in
MH1C1 cells
We previously observed that in the MH1C1 cells, unlike
normal hepatocytes, PGE2 induced phosphorylation of the
EGFR and activated ERK by a mechanism that was sensitive
to EGFR inhibition [37]. Further investigation (Figure 1),
showed that in addition to inducing phosphorylation ofA
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We next investigated which prostaglandin receptors are
expressed in the MH1C1 cells. qRT-PCR analysis
revealed mRNA expression of EP1, EP4, and FP subtypes
of prostaglandin receptors, whereas only traces of EP3
receptor mRNA were present and no EP2 expression
was detected (Figure 2A). The hepatocytes expressed
EP2, EP3, EP4, and FP (Figure 2B).
The available evidence indicates that the EP4 receptors
are coupled to Gs proteins and adenylyl cyclase activity
and thereby cAMP elevation, and that FP receptors
couple to Gq proteins which mediate activation of
phospholipase C-β (PLCβ) leading to formation of inosi-
tol trisphosphate (InsP3) and diacylglycerol (DAG)
[27,43]. The G proteins and signalling mechanisms sti-
mulated by the EP1 receptors are not fully clarified
[43,44]. PGE2 has high affinity for EP1 and EP4 recep-
tors, and while the FP receptor has the highest affinity
for PGF2α, PGE2 also binds to this receptor [27]. In the
MH1C1 cells no cAMP response to PGE2 could be
detected, although the cells had a functional adenylyl
cyclase, as shown by their marked cAMP elevation in
response to the β-adrenergic agonist isoproterenol
(Figure 2C left). In contrast, PGE2 stimulated accumulationA
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other prostaglandin receptors, suggesting that it is a se-
lective antagonist at the FP receptor [45]. Further support
for a functional role of FP receptors in these cells was
obtained in the results given in Figure 3D, demonstrating
that AL8810 inhibited the inositol phosphate accumula-
tion induced by the FP receptor agonist fluprostenol.
Taken together, these results suggest that the PGE2-
induced transactivation of EGFR in MH1C1 hepatoma
cells is mediated primarily by FP receptors and signalling
via Gq and PLCβ.
Evidence of a role for Ca2+, but not PKC, in the
PGE2-induced transactivation of EGFR
We next tried to determine which pathways downstream
of PLCβ are mediating the PGE2-induced transactivation
of EGFR. InsP3 and DAG stimulate cytosolic Ca
2+ re-
lease and protein kinase C (PKC) activity, respectively.Pretreatment of the cells with the PKC inhibitor
GF109203X did not prevent the effects of PGE2 on the
phosphorylation of the EGFR, ERK, or Akt in the
MH1C1 cells (Figure 4A). Furthermore, the data in
Figure 4B, comparing PGE2 and the direct PKC activator
tetradecanoylphorbol acetate (TPA), showed that TPA
did not mimic the effect of PGE2 on Akt, and its stimu-
lation of ERK, unlike the effect of PGE2, was blocked by
GF109203X. Interestingly, pretreatment of the cells with
GF109203X consistently increased basal and PGE2-
induced Akt phosphorylation in the cells. This might re-
sult from a reduced feedback inhibition by PKC [47]. In
contrast to TPA, thapsigargin, which increases the intra-
cellular Ca2+ level by inhibiting the ‘sarco/endoplasmic
reticulum Ca2+-ATPase’ (SERCA) pump [48], induced
gefitinib-sensitive phosphorylation of EGFR, ERK, and
Akt (Figure 4C). Taken together, these data suggest that
Ca2+ rather than PKC mediates the PGE2-induced trans-
activation of the EGFR in these cells.
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of the EGFR
To further elucidate mechanisms involved in transactiva-
tion of the EGFR, we investigated the effects of Src inhi-
bitors. As shown in Figure 5A, pretreatment of the cells
with the Src inhibitor CGP77675 almost completely
abolished the PGE2-induced phosphorylation of EGFR
and the activation of ERK and Akt, but, in contrast, had
little or no effect on the phosphorylation of these pro-
teins elicited by EGF. The Src inhibitor PP2 similarly
prevented the phosphorylation of ERK in response to
PGE2, while the response to EGF was not significantly
affected (Figure 5B). These results suggest an involve-
ment of a Src family kinase in the PGE2-induced trans-
activation of EGFR in MH1C1 cells.
Previous evidence has implicated proteinases of the ‘a-
disintegrin-and-metalloproteinase’ (ADAM) family in
EGFR transactivation by GPCRs in various cells
[2,49,50]. To test the role of ADAMs in the PGE2-
induced EGFR transactivation in MH1C1, we pretreated
the cells with GM6001, which is a broad-spectrum
metalloproteinase inhibitor [50]. This pretreatment
resulted in complete inhibition of PGE2-inducedphosphorylation of EGFR, ERK, and Akt, while the EGF-
induced phosphorylation of these proteins was not
affected (Fig 5C and D), indicating that the transactiva-
tion is dependent on mechanisms involving ADAM-
mediated release of EGFR ligand(s). We also examined
the effect of this inhibitor in the primary cultures of rat
hepatocytes, and found neither inhibition of PGE2-
induced phosphorylation of ERK and Akt in these cells
nor any effect on EGF-induced phosphorylation of
EGFR, ERK and Akt (Figure 5E).
Discussion
We have shown that in the MH1C1 hepatocarcinoma cells
stimulation with PGE2 or PGF2α causes phosphorylation of
the EGFR and an EGFR-dependent phosphorylation of
ERK and Akt, indicating that these prostaglandins induced
transactivation of EGFR. Further study of the PGE2 effect
suggested that the transactivation was mediated by the
Gq-coupled FP receptor and activation of PLCβ with
downstream signalling by Ca2+ release, Src, and ADAM-
mediated shedding of membrane-bound EGFR ligand pre-
cursors. In contrast, in primary hepatocytes, PGE2 did not
phosphorylate the EGFR, and gefitinib did not prevent
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Figure 5 Effect of Src and MMP inhibitors on phosphorylation of EGFR and downstream targets. A) MH1C1 cells were pretreated for
90 min with the Src inhibitor CGP 77675 (10 μM). Cells were then stimulated with either PGE2 (100 μM) or EGF (10 nM) for 5 min before they
were harvested and immunoblotting performed as described in Materials and Methods. Representative blots of at least three experiments. B)
MH1C1 cells were pretreated for 30 min with the Src inhibitor PP2 (10 μM). Cells were then stimulated with either PGE2 (100 μM) or EGF (10 nM)
for 5 min before they were harvested and immunoblotting performed as described in Materials and Methods. Representative blots of two
experiments. C) MH1C1 cells were pretreated for 30 min with increasing concentrations of the metalloproteinase inhibitor GM6001. Cells were
then stimulated with PGE2 (100 μM) for 5 min before they were harvested and immunoblotting performed as described in Materials and
Methods. Representative blots of three experiments D) MH1C1 cells were pretreated for 30 min with the metalloproteinase inhibitor GM6001
(10 μM). Cells were then stimulated with either PGE2 (100 μM) or EGF (10 nM) for five minutes before they were harvested and immunoblotting
performed as described in Materials and Methods. Representative blots of at least three experiments E) Same experiment as in D) performed in
hepatocytes. Representative blots of at least three experiments.
Tveteraas et al. Journal of Experimental & Clinical Cancer Research 2012, 31:72 Page 8 of 11
http://www.jeccr.com/content/31/1/72phosphorylation of Akt or ERK after PGE2-stimulation,
which lends further support to our previous data suggest-
ing that GPCR agonists do not transactivate the EGFR in
normal rat hepatocytes, but rather signal via mechanisms
that synergistically enhance the effects of EGF
[34,37,38,51,52] (Figure 6).
Different receptors and pathways may be involved in
mitogenic and tumour-promoting effects of prostaglan-
dins [28]. qRT-PCR analysis showed that the prostaglan-
din receptors expressed in these cells are EP1, EP4, and
FP. No significant increase in cAMP accumulation was
detected, in accordance with previous results [53], sug-
gesting either that the EP4 protein levels are low, or thatthese receptors are functionally uncoupled from adenylyl
cyclase. In contrast, PGE2 stimulated accumulation of
inositol phosphates. Pretreatment with the EP4 antagon-
ist L161982 or the EP1 antagonist SC51322, had no ef-
fect on the PGE2-induced phosphorylation of EGFR,
ERK, or Akt, while the phosphorylation of these proteins
were markedly inhibited by the FP antagonist AL8810.
PGF2α, which binds to FP receptors with high affinity,
mimicked the effects of PGE2. Together, these results
suggest that in contrast to the normal rat hepatocytes,
where the effect of PGE2 seems to be mediated primarily
through the EP3 receptor [37,52,54], the MH1C1 cells,
which do not express EP3 receptors, respond to PGE2
Figure 6 Mechanisms by which PGE2 interacts with
EGFR-mediated signalling in hepatocytes and MH1C1
hepatocarcinoma cells. A) In normal rat hepatocytes, PGE2 does
not elicit transactivation of EGFR, but induces upregulation of the
effectiveness in Ras/ERK and PI3K/Akt pathways downstream of
EGFR, leading to an enhanced mitogenic response to EGF family
growth factors [37,38,51]. Although not fully clarified, previous
studies have indicated that this effect of PGE2 is mediated primarily
through EP3 receptors and Gi proteins, requires several hours to
develop, and is most likely a result of altered gene expression
[34,37,38,51,52]. B) In MH1C1 rat hepatocarcinoma cells, PGE2
transactivates EGFR and thereby activates the Ras/ERK and PI3K/Akt
signalling pathways. The results of the present study suggest that
this effect is exerted via FP receptors, Gq proteins, PLCβ, intracellular
Ca2+ (but not PKC), Src, and ADAM-mediated release of EGFR
ligands.
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that expression of EP3 receptors has been found to be
suppressed or absent in colon cancer in vivo and
in vitro, as compared to normal mucosa [55].
PLCβ can regulate cellular functions via two distinct
pathways, involving DAG-mediated activation of PKC and
InsP3-induced release and elevation of cytosolic Ca
2+, re-
spectively. Our findings suggest that in the MH1C1 cells,
the effect of PGE2 was mediated through Ca
2+, since it
was not mimicked by TPA and not inhibited by a PKC
blocker, while thapsigargin, which elevates intracellular
Ca2+, mimicked the PGE2 effect, inducing a gefitinib-
sensitive phosphorylation of EGFR.
In other cells, both ligand-dependent and ligand-
independent mechanisms have been found to mediateEGFR transactivation [5]. Ligand-dependent mechanisms
involve the release of EGFR agonists by cleavage and
shedding of membrane-associated precursors by protei-
nases of the ADAM family [2,49]. Ligand-independent
mechanisms have been suggested to involve intracellular
molecules including Src family kinases and Pyk2
[1,3,56,57]. Han et al. reported that in Hep3B cells, PGE2
induced phosphorylation of the EGFR through EP1
receptors and an intracellular mechanism involving Src
[57]. Itabashi et al. demonstrated that in some hepato-
carcinoma cell lines EGFR transactivation triggered by
angiotensin II stimulation was mediated through release
of EGFR ligand by members of the ADAM family [58].
In the MH1C1 cells, we observed that Src inhibitors
abolished PGE2-stimulated phosphorylation of the
EGFR, ERK, and Akt, but in contrast, only slightly
affected the response to EGF, suggesting a role of Src in
the transactivation in these cells. We also found evi-
dence for the involvement of ligand shedding in the
transactivation of EGFR after PGE2 stimulation, since
pretreatment of the cells with the metalloproteinase in-
hibitor GM6001 almost completely prevented PGE2-
induced, but not EGF-induced, phosphorylation of
EGFR, Akt and ERK. GM6001 did not affect the effects
of PGE2 in the normal hepatocytes. The lack of transac-
tivation in response to PGE2 in these cells could be due
to the low expression of metalloproteinases in hepato-
cytes as compared to hepatocarcinoma cells [59]. These
results indicate that in the MH1C1 cells Src is involved
in activating ADAMs rather than directly stimulating
the EGFR, thus combining the two mechanisms. The in-
volvement of both Src and ADAMs has been reported in
normal gastrointestinal epithelial and colon cancer cell
lines [60].
Several signalling pathways seem to be important in
hepatocarcinomas [19], and there is evidence that both
EGFR-mediated mechanisms and the COX/prostaglan-
din system may be involved in the pathobiology of these
tumours [17,18,20,35,36]. The results of the present
study suggest a functional interaction between the EGFR
and the prostaglandins. It has been proposed that trans-
activation can explain the mitogenic effect of GPCR
ligands in some cell systems [61] and that it represents a
means of diversifying signalling in the cells, by linking
the input from a large number of ligands stimulating
GPCRs to the pleiotypic and potentially tumorigenic
effects of the EGFR [62]. However, there seems to be
great variation between cell types with respect to the dif-
ferent pathways involved in the signalling. We have re-
cently shown that while neurotensin, a GPCR agonist,
activates ERK and Akt in an EGFR-independent way in
pancreatic cancer Panc-1 cells, as also found by others
[63], and activates ERK and Akt via EGFR transactiva-
tion in the colon cancer cell line HT 29, neurotensin
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in the colon cancer cell line HCT 116 [12].
In the present study we have shown that PGE2 has dif-
ferent ways of stimulating the cells, acting by FP-
mediated EGFR transactivation in the hepatocarcinoma
cells, whereas the effect is mediated mainly via EP3
receptors without any involvement of the EGFR in the
hepatocytes [37,52]. This is further evidence of the diver-
sity of intracellular cross-talk and underscores the im-
portance of investigating such mechanisms in order to
better understand the signalling in cancer cells.
Conclusion
The results indicate that in MH1C1 cells, unlike normal
hepatocytes, PGE2 activates the MEK/ERK and PI3K/
Akt pathways by transactivation of the EGFR, thus diver-
sifying the GPCR-mediated signal. The data also suggest
that the underlying mechanisms in these cells involve FP
receptors, PLCβ, Ca2+, Src, and proteinase-mediated re-
lease of membrane-associated EGFR ligand(s).
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